STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology

Study Highlights the Life-Saving Potential of Obesity Drugs and Strengthens the Bullish Case for Viking Therapeutics

byLuca Blaumann
October 17, 2024
in Biotechnology, Mid-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

VKTX’s Innovative Drug Candidates Could Unlock Significant Value for Patients and Investors

A recent study has shone new light on the life-saving potential of GLP-1-based obesity drugs, further solidifying the bullish outlook for Viking Therapeutics (VKTX). As the battle against obesity intensifies, new therapies are increasingly viewed as crucial tools in reducing obesity-related deaths. Despite these benefits, the accessibility of these drugs remains limited due to financial barriers and restrictive insurance coverage. This gap in access represents a significant issue, but for companies like Viking Therapeutics, it also offers an opportunity to make a substantial impact on public health and generate meaningful shareholder value.

The study underscores the importance of expanding access to obesity drugs such as GLP-1 agonists, which can significantly improve survival rates among patients with obesity. Viking Therapeutics’ promising drug candidate VK2735, with both oral and subcutaneous (subQ) delivery options, is well-positioned to address these needs and potentially redefine how obesity treatments are accessed and administered. With upcoming data releases and pivotal trials on the horizon, VKTX is emerging as a key player in the fight against obesity.

Obesity: A Public Health Crisis

Obesity is a major public health issue in the U.S., affecting over 40% of the population and contributing to a host of related diseases such as diabetes, cardiovascular disease, and certain cancers. Despite its significant impact on health and mortality, obesity is often under-recognized as a direct cause of death. The new study reveals that expanding access to GLP-1-based obesity drugs could save thousands of lives annually. However, access remains unequal, with patients on private insurance more likely to benefit from these drugs than those on Medicare or without insurance.

The study suggests that with current access levels, approximately 6,000 deaths could be prevented annually, mostly among privately insured patients. By improving access, as many as 10,000 additional lives could be saved among Medicare beneficiaries, and 3,000 among uninsured patients. This stark disparity highlights the need for expanded drug coverage and increased availability of these life-saving treatments.

VK2735: A Promising Candidate in the Fight Against Obesity

Viking Therapeutics is making significant strides with its GLP-1 drug candidate, VK2735. The company is developing both oral and subQ versions of the drug, offering flexibility and broader access to patients who may have difficulty affording or obtaining these medications through traditional channels.

In a recent Phase 1 study, VK2735 demonstrated impressive results. Patients who took the oral form of the drug experienced a dose-dependent reduction in body weight over a 28-day period, with the highest dose group achieving a 5.3% reduction in weight compared to a 2.1% reduction in the placebo group. Notably, the drug exhibited a favorable safety profile, with most adverse events limited to mild nausea and no vomiting, making it a promising option for wider use.

The company is continuing to explore higher doses of VK2735, with additional data expected to be unveiled at the upcoming ObesityWeek conference on November 3rd. These results could further bolster the case for VK2735 as a best-in-class obesity treatment, unlocking significant value for patients and shareholders alike.

The Case for Over-the-Counter Access

Viking Therapeutics’ innovation in GLP-1 therapy doesn’t stop with prescription options. A survey conducted among primary care physicians (PCPs) revealed that approximately 50% of respondents would support the availability of an oral obesity agent over-the-counter (OTC). This would be a game-changer, making obesity treatments far more accessible to a broader population, particularly those facing financial barriers.

The OTC potential for VK2735 is an exciting prospect that could attract partnerships with larger pharmaceutical companies, seeking to capitalize on this opportunity. Expanding access through OTC availability would not only improve patient outcomes but also extend the product’s life cycle, providing long-term value for VKTX.

Upcoming Catalysts and Investment Potential

Viking Therapeutics’ lead candidate, VK2809, a THR-β agonist for non-alcoholic steatohepatitis (NASH), continues to show promise as well. The company’s upcoming catalysts include additional data from VK2735 in the second half of 2024 and the initiation of a Phase 2 study. Moreover, the outcome of an End-of-Phase 2 (EOP2) meeting with the FDA for VK2809 in NASH could pave the way for continued development into Phase 3, further boosting VKTX’s potential valuation.

With a combination of promising drug candidates, upcoming clinical milestones, and a favorable market landscape, Viking Therapeutics presents a compelling investment opportunity. The company’s innovative approach to obesity and NASH treatments could unlock significant value not only for patients in need but also for investors seeking upside in a growing therapeutic market.

You might like this article:Here are the Nuclear Stocks You Need To Watch After Amazon’s Nuclear Investment

Tags: analystBreakingGrowthMoversNewsStock Market
Previous Post

Here are the Nuclear Stocks You Need To Watch After Amazon’s Nuclear Investment

Next Post

Ulta Beauty: Long-Term Prospects Shine Amidst Industry Challenges

Related Posts

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

byLiliana Vida
November 11, 2026
0

Quantum computing company reports $4.5 million in revenue, strong year-to-date bookings, and potential access to $100 million in federal funding....

investing

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

byLuca Blaumann
November 10, 2026
0

Quantum computing company beats earnings expectations, reports $503 million in liquidity, and advances major technology initiatives across global markets. D-Wave...

Next Post

Ulta Beauty: Long-Term Prospects Shine Amidst Industry Challenges

Latest News

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

Based on Your Interest

Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026
Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026

Recommended

Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Aerospace & Defense

SpaceX Secures Reported $45 Billion AI Infrastructure Deal With Anthropic

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%
  • CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

November 12, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.